BioWorld - Sunday, November 24, 2024
See today's BioWorld
X

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options
To read the full story, subscribe or sign in.

Cullinan ends $625M deal, returns Harbour’s cancer drug

Aug. 12, 2024
By Marian (YoonJee) Chu
No Comments
Cullinan Therapeutics Inc. terminated development of Harbour Biomed Holdings Ltd.’s bispecific B7H4 x 4-1BB immune activator, CLN-418 (HBM-7008), after reviewing phase I data.
BioWorld Deals and M&A License Cancer Immune Bispecific antibody Private placement Asia-Pacific China U.S.